Alpivab

RSS

peramivir

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Alpivab has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 09/12/2020

Authorisation details

Product details
Name
Alpivab
Agency product number
EMEA/H/C/004299
Active substance
Peramivir
International non-proprietary name (INN) or common name
peramivir
Therapeutic area (MeSH)
Influenza, Human
Anatomical therapeutic chemical (ATC) code
J05AH03
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Biocryst
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
13/04/2018
Contact address

Biocryst
Atlantic Avenue
Westpark Business Campus
Shannon V14 YX01
Ireland

Product information

20/11/2020 Alpivab - EMEA/H/C/004299 - T/0004

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating